Study of AZD2389 Safety, Tolerability, and Pharmacodynamics in Adults With Steatotic Liver Disease and Advanced Fibrosis (NCT07610837)
A Phase IIa, Randomised, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of AZD2389 in Adult Participants With Steatotic Liver Disease and Advanced Fibrosis (BRAVO)
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to evaluate the safety, tolerability, and pharmacodynamic effects of AZD2389 in adult participants with steatotic liver disease (SLD) and advanced fibrosis.
Who can join: Review the eligibility criteria below.
Location: Research Site — Chandler, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (20 Sites)
- Research Site — Chandler, Arizona
- Research Site — Tucson, Arizona
- Research Site — Jupiter, Florida
- Research Site — Miami, Florida
- Research Site — Port Orange, Florida
- Research Site — Kansas City, Missouri
- Research Site — St Louis, Missouri
- Research Site — Las Vegas, Nevada
- Research Site — Morehead City, North Carolina
- Research Site — Raleigh, North Carolina
- Research Site — Westlake, Ohio
- Research Site — Yukon, Oklahoma
- Research Site — Clarksville, Tennessee
- Research Site — Austin, Texas
- Research Site — Denison, Texas
- Research Site — Georgetown, Texas
- Research Site — Houston, Texas
- Research Site — Houston, Texas
- Research Site — San Antonio, Texas
- Research Site — San Antonio, Texas
📞 Contact the Study Coordinator
Phone: (877) 240-9479
Email: information.center@astrazeneca.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
- 💵 Compensation indicated: Approximately 52 participants will be randomised to receive AZD2389 and approximately 52 participants will receive placebo.
Explore by condition: All Liver Fibrosis clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.